US-based biopharmaceutical company Provention Bio has raised $28.4m through a private placement featuring Johnson & Johnson Innovation – JJDC, a subsidiary of pharmaceutical group Johnson & Johnson.
MDB Capital Group, the company builder that co-founded Provention, was placement agent for the offering, which included diabetes research finance organisation JDRF’s T1D Fund.
Provention is developing therapeutics and technology that can predict and prevent immune-mediated disease. It could end up preventing chronic autoimmune and inflammatory diseases like type 1 diabetes as well…
